Johnstone P A, Sindelar W F
Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland.
Pancreas. 1993 Sep;8(5):535-9. doi: 10.1097/00006676-199309000-00001.
In a prospectively randomized trial evaluating pancreatic resection with adjuvant radiotherapy (intraoperative radiotherapy [IORT] vs. external beam radiotherapy [EBRT]), lymph nodal involvement was examined and correlated with outcome. Twenty-six patients underwent pancreatic resection and received either IORT or EBRT (Stages II-IV). Patients who were stage I received surgery alone. Regional nodal metastases were present in 15 of 26 (57%) patients. Seven patients suffered treatment-related mortality. Survival, mortality, and morbidity were unaffected by the type of radiotherapy. The survival of patients with negative nodes (median survival 24 months, range 10 to > 109) appeared superior to the survival of patients with nodal involvement (median survival 11.5 months; range 4-39). Even in patients with locally advanced disease extending into extrapancreatic tissues, two node-negative patients appeared to survive longer (12 and 53 months) than 10 node-positive patients with similarly extensive local disease (median survival 11.5 months; range 4-39). Local disease control, however, appeared to be independent of nodal involvement, with eventual local recurrences in 6 of 8 node-negative patients and in 4 of 7 node-positive patients who were evaluable for local disease control by autopsy or by antemortem laparotomy.
在一项前瞻性随机试验中,评估了胰腺癌切除术后辅助放疗(术中放疗[IORT]与外照射放疗[EBRT])的效果,并研究了淋巴结受累情况及其与预后的相关性。26例患者接受了胰腺癌切除术,并接受了IORT或EBRT(II-IV期)。I期患者仅接受手术治疗。26例患者中有15例(57%)存在区域淋巴结转移。7例患者死于治疗相关并发症。放疗类型对生存率、死亡率和发病率无影响。无淋巴结转移患者的生存率(中位生存期24个月,范围10至>109个月)似乎优于有淋巴结转移患者的生存率(中位生存期11.5个月;范围4-39个月)。即使在局部晚期疾病已侵犯胰腺外组织的患者中,2例无淋巴结转移患者的生存期(12个月和53个月)似乎也长于10例有同样广泛局部病变的有淋巴结转移患者(中位生存期11.5个月;范围4-39个月)。然而,局部疾病控制似乎与淋巴结受累无关,8例无淋巴结转移患者中有6例最终出现局部复发,7例有淋巴结转移患者中有4例通过尸检或生前剖腹探查可评估局部疾病控制情况,也出现了局部复发。